FDA recommends changes to TNF antagonist labels

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1265, 2009-01, pp. : 1-1

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

FDA recommends label updates for some immunosuppressants

By  

Reactions Weekly, Vol. 1, Iss. 1261, 2009-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Institute of Medicine recommends US FDA reforms

By  

Inpharma, Vol. 1, Iss. 1559, 2006-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

FDA recommends against off-label sildenafil use in children

By  

Reactions Weekly, Vol. 1, Iss. 1418, 2012-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

A US FDA advisory committee recommends that alosetron [`Lotronex'; GlaxoSmithKline] be reintroduced

By  

Inpharma, Vol. 1, Iss. 1336, 2002-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

TNF Binding Protein of Variola Virus Acts as a TNF Antagonist at Epicutaneous Application

By  

Current Pharmaceutical Biotechnology, Vol. 16, Iss. 1, 2015-01 ,pp. : 72-76

Bentham Science Publishers

Access to resources Recommend Favorite